| Selective survival of naturally occurring human CD4+ CD25+ Foxp3+ regulatory T cells cultured with rapamycin L Strauss, TL Whiteside, A Knights, C Bergmann, A Knuth, A Zippelius The Journal of Immunology 178 (1), 320-329, 2007 | 424 | 2007 |
| MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells LJ Vella, A Pasam, N Dimopoulos, M Andrews, A Knights, AL Puaux, ... Cancer immunology research 2 (4), 351-360, 2014 | 145 | 2014 |
| Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules MT Bethune, XH Li, J Yu, J McLaughlin, D Cheng, C Mathis, BH Moreno, ... Proceedings of the National Academy of Sciences 115 (45), E10702-E10711, 2018 | 66 | 2018 |
| MAGE‐C1/CT‐7 expression in plasma cell myeloma: sub‐cellular localization impacts on clinical outcome M Tinguely, B Jenni, A Knights, B Lopes, D Korol, V Rousson, ... Cancer science 99 (4), 720-725, 2008 | 65 | 2008 |
| Prediction of an HLA-DR-binding peptide derived from Wilms’ tumour 1 protein and demonstration of in vitro immunogenicity of WT1 (124–138)-pulsed dendritic cells generated … A Knights, A Zaniou, RC Rees, G Pawelec, L Müller Cancer Immunology, Immunotherapy 51, 271-281, 2002 | 52 | 2002 |
| Processing and cross-presentation of individual HLA-A,-B, or-C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery NC Robson, T McAlpine, AJ Knights, M Schnurr, A Shin, W Chen, ... Blood, The Journal of the American Society of Hematology 116 (2), 218-225, 2010 | 42 | 2010 |
| Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy AJ Knights, J Fucikova, A Pasam, S Koernig, J Cebon Cancer Immunology, Immunotherapy 62, 321-335, 2013 | 40 | 2013 |
| MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma A Curioni-Fontecedro, AJ Knights, M Tinguely, N Nuber, C Schneider, ... Leukemia 22 (8), 1646-1648, 2008 | 40 | 2008 |
| Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients SM Walton, M Gerlinger, O de la Rosa, N Nuber, A Knights, A Gati, ... The Journal of Immunology 177 (11), 8212-8218, 2006 | 38 | 2006 |
| Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells L Müller, A Knights, G Pawelec The Hematology Journal 4 (1), 57-66, 2003 | 38 | 2003 |
| HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides MG Mathieu, AJ Knights, G Pawelec, CL Riley, D Wernet, FA Lemonnier, ... Cancer Immunology, Immunotherapy 56, 1885-1895, 2007 | 35 | 2007 |
| Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients AJ Knights, N Nuber, CW Thomson, O de la Rosa, E Jäger, JM Tiercy, ... Cancer immunology, immunotherapy 58, 325-338, 2009 | 34 | 2009 |
| Melanoma vaccines: developments over the past 10 years O Klein, C Schmidt, A Knights, ID Davis, W Chen, J Cebon Expert review of vaccines 10 (6), 853-873, 2011 | 33 | 2011 |
| Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1 J Cebon, A Knights, L Ebert, H Jackson, W Chen Expert review of vaccines 9 (6), 617-629, 2010 | 30 | 2010 |
| MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol. Res. 2014; 2 … LJ Vella, A Pasam, N Dimopoulos, M Andrews, A Knights, AL Puaux, ... CIR-13-0181.[Abstract][CrossRef][Google Scholar], 0 | 29 | |
| Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma K Woods, AJ Knights, M Anaka, RB Schittenhelm, AW Purcell, A Behren, ... Journal for ImmunoTherapy of Cancer 4, 1-14, 2016 | 26 | 2016 |
| QuantiFERON-TB performance enhanced by novel Mycobacterium tuberculosis-specific antigens M Losi, AJ Knights, F Mariani, AM Altieri, G Paone, AG Loxton, ... European Respiratory Journal 47 (2), 660-664, 2016 | 20 | 2016 |
| A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of … AJ Knights, AO Weinzierl, T Flad, BA Guinn, L Mueller, GJ Mufti, ... Leukemia 20 (6), 1067-1072, 2006 | 19 | 2006 |
| A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen RY Zhao, NA Mifsud, K Xiao, KF Chan, S Oveissi, HM Jackson, ... Public Library of Science 7 (9), e44707, 2012 | 11 | 2012 |
| MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells LJ Vella, A Pasam, N Dimopoulos, M Andrews, AL Puaux, J Louahed, ... Journal for ImmunoTherapy of Cancer 1, 1-1, 2013 | 5 | 2013 |
